acute respiratory distress syndrome
Conditions
Interventions
Observation group:None
Sponsors
Zhongshan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1: Age >= 18 years old; 2: Meets the new ARDS global definition for 2023,As follows: a) Onset time: Respiratory symptoms must occur or worsen within one week after the occurrence of ARDS-susceptible risk factors. b) Imaging features: Chest X-ray or CT shows bilateral lung infiltrates, or ultrasound-identified loss of bilateral lung ventilation function by a well-trained operator, which cannot be fully explained by pleural effusion, atelectasis, or nodules/masses. c) Cause of pulmonary edema: Respiratory failure cannot be fully explained by heart failure or fluid overload; if there are no related risk factors, objective tests (such as Doppler echocardiography) should be performed to rule out hydrostatic pulmonary edema. d) Hypoxemia: For patients receiving invasive or non-invasive mechanical ventilation with positive end-expiratory pressure (PEEP) = 5 cmH2O, or high-flow nasal cannula oxygen therapy (HFNC) with a flow rate = 30 L/min, the ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) = 300 mmHg or the ratio of peripheral oxygen saturation to fraction of inspired oxygen (SpO2/FiO2) = 315 mmHg with SpO2 = 97%. e) ARDS in resource-limited settings: Patients only need to meet SpO2/FiO2 = 315 mmHg (SpO2 = 97%), without the requirement of PEEP = 5 cmH2O, minimum inspired oxygen flow rate, or specific respiratory support equipment.
Exclusion criteria
Exclusion criteria: 1: Pregnancy status; 2: Due to severe underlying diseases, the expected survival time is less than 28 days, such as the terminal stage of malignant tumors; 3: Have participated in interventional clinical trials within the last 3 months; 4: Refuse to provide informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Metabolomics;Proteomics;Transcriptomics; | — |
Secondary
| Measure | Time frame |
|---|---|
| C-reactive protein;Procalcitonin;Cytokine;Lymphocyte subsets;Salivary liquefied glycochain antigen (KL-6);Lactic acid;Myocardial marker;SOFA scoring;APACHE II Scoring; | — |
Countries
China
Contacts
Public ContactZhenju Song
Zhongshan Hospital,Fudan University
Outcome results
None listed